Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $12.94 USD
Change Today -0.27 / -2.04%
Volume 281.7K
SRNE On Other Exchanges
As of 8:10 PM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

sorrento therapeutics inc (SRNE) Snapshot

Previous Close
Day High
Day Low
52 Week High
05/15/15 - $15.00
52 Week Low
10/14/14 - $3.10
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

sorrento therapeutics inc (SRNE) Related Businessweek News

No Related Businessweek News Found

sorrento therapeutics inc (SRNE) Details

Sorrento Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of proprietary drug therapeutics for addressing unmet medical needs in the United States, Europe, and internationally. The company primary therapeutic focus is oncology, including the treatment of chronic cancer pain, as well as developing therapeutic products for other indications, such as immunology and infectious diseases. Its lead product, Cynviloq, is polymeric, albumin-free nanoparticle paclitaxel formulation, approved and marketed in South Korea for metastatic breast cancer (MBC), non-small cell lung cancer (NSCLC), and ovarian cancer under the trade name Genexol-PM. Cynviloq has also completed Phase I, Phase II, and Phase III clinical trials, and post-marketing surveillance studies in MBC, NSCLC, ovarian, pancreatic, and bladder cancer. The company is also developing resiniferatoxin, a non-opiate, ultra potent, and selective agonist of the TRPV-1 receptor for intractable pain in end-stage disease. In addition, the company’s preclinical human therapeutic monoclonal antibodies include human anti- PD-L1 and anti-PD-1 checkpoint inhibitors; antibody drug conjugates; and bispecific antibodies, as well as Chimeric Antigen Receptor Tumor-attacking Neukoplast for adoptive cellular immunotherapies. It has a collaboration agreement with Conkwest Incorporated to generate and develop products for adoptive immunocellular therapy utilizing Neukoplast cells and chimeric antigen receptors; and NantWorks, Inc. to develop anti-cancer immunotherapies. Sorrento Therapeutics, Inc. was founded in 2006 and is headquartered in San Diego, California.

66 Employees
Last Reported Date: 03/16/15
Founded in 2006

sorrento therapeutics inc (SRNE) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $582.5K
Chief Commercial Officer and Executive Vice P...
Total Annual Compensation: $341.2K
Executive Vice President of Clinical and Regu...
Total Annual Compensation: $337.5K
Compensation as of Fiscal Year 2014.

sorrento therapeutics inc (SRNE) Key Developments

Advaxis, Inc. and Sorrento Therapeutics, Inc. Form Collaboration to Evaluate Combinations of Advaxis's Lm-LLO Immunotherapy Technology and Sorrento's Immunomodulatory Antibodies

Advaxis, Inc. has entered into a non-exclusive research and clinical trial collaboration agreement with Sorrento Therapeutics, Inc. to evaluate combinations of Advaxis'sLm-LLO cancer immunotherapy technology platform, including ADXS-HPV, ADXS-PSA and ADXS-HER2, with Sorrento's fully human antibodies targeting immune checkpoints, including GITR, OX40, LAG-3 and TIM-3. Sorrento has the diverse fully human antibody libraries in the industry designed to facilitate rapid identification and selection of highly specific therapeutic monoclonal antibody (mAb) product candidates. Advaxis's preclinical program for ADXS-HPV previously examined its therapeutic potential in combination with agonistic research antibodies, including anti-OX40 and anti-GITR. Preclinical data demonstrated that the combination of ADXS-HPV with agonistic research antibodies led to significant inhibition of tumor growth and prolonged survival in tumor-bearing mice. Complete regression of established tumors occurred in 40% and 60% of animals treated with ADXS-HPV in combination with anti-OX40 and anti-GITR antibodies, respectively (AACR Abstract #LB-229 [2]). Under the terms of the agreement, Advaxis will conduct the studies and the companies will equally share the expenses. The companies hope to commence the first of the two planned combination studies in 2016. Results from the studies will be used to determine whether further clinical development of specific combinations is warranted.

Sorrento Therapeutics, Inc. Announces Positive TRIBECA Registrational Study Results

Sorrento Therapeutics, Inc. announced positive results from recently analyzed pharmacokinetic (PK) data from its TRIBECA (TRIal establishing BioEquivalence between Cynviloq and Albumin-bound paclitaxel) registrational trial. Data analysis suggests that Cynviloq meets the bioequivalence (BE) criteria for both total and unbound paclitaxel. The ongoing safety assessment from treated patients continues to reveal no unexpected adverse events and the safety data is consistent with the toxicity profile reported in the literature with albumin-bound paclitaxel.

Sorrento Therapeutics, Inc. Announces Management Changes

Sorrento Therapeutics, Inc. announced the appointments of David H. Deming to its Board of Directors and Mark W. Durand as Chief Financial Officer. Mr. Deming replaced Mr. Durand as a member of the Board, who stepped down to assume the role of Chief Financial Officer. In his Board capacity, Mr. Deming will Chair the Audit Committee and be a member of the Compensation Committee. Mr. Durand has nearly 30 years of pharmaceutical industry experience in a variety of leadership roles in finance, business development and general management. Most recently, he was an independent strategic consultant for emerging pharmaceutical firms.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SRNE:US $12.94 USD -0.27

SRNE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for SRNE.
View Industry Companies

Industry Analysis


Industry Average

Valuation SRNE Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 125.0x
Price/Book 4.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 106.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SORRENTO THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at